Prostaglandin E2 (PGE2) is a bioactive lipid that mediates a wide range of physiologic effects and plays a central role in inflammation and cancer. PGE2 is generated from arachidonic acid by the sequential actions of the COX and terminal synthases (PGES). Increased levels of COX-2, with a concomitant elevation of PGE2, are often found in colorectal cancers (CRC), providing the rationale for the use of COX-2 inhibitors for chemoprevention. Despite their proven efficacy in cancer prevention, however, COX-2 inhibitors exhibit dose-dependent toxicities that are mediated in part by their nonspecific reduction of essential prostanoids, thus limiting their chemopreventive benefit. To achieve enhanced specificity, recent efforts have been directed toward targeting the inducible terminal synthase in the production of PGE2, microsomal PGES (mPGES-1). In the present study, we show that genetic deletion of mPGES-1 affords significant protection against carcinogen-induced colon cancer. mPGES-1 gene deletion results in an about 80% decrease in tumor multiplicity and up to a 90% reduction in tumor load in the distal colon of azoxymethane (AOM)-treated mice. Associated with the striking cancer suppression, we have identified a critical role for PGE2 in the control of immunoregulatory cell expansion (FoxP3-positive regulatory T cells) within the colon-draining mesenteric lymph nodes, providing a potential mechanism by which suppression of PGE2 may protect against CRC. These results provide new insights into how PGE2 controls antitumor immunity. Cancer Prev Res; 4(8); 1198–208. ©2011 AACR.

Selective inhibition of prostaglandin E2 (PGE2) synthesis via pharmacologic targeting of mPGES-1 may provide chemopreventive efficacy while limiting the toxicity that is often associated with long-term use of COX-2 inhibitors (1). mPGES-1 is an inducible terminal synthase with only moderate expression under normal physiologic conditions (2). However, coordinated induction of mPGES-1 and COX-2 is often observed within a variety of cancer types (3). Our laboratory recently reported that genetic deletion of mPGES-1 in Apc mutant mice significantly suppressed intestinal tumorigenesis, a protective effect that occurred in the absence of significant metabolic shunting of the COX-2 product, PGH2, to other prostaglandins (4).

Despite the profound suppression in tumor formation that was observed in this earlier study, the effect of mPGES-1 deletion in the colon was less apparent due to the propensity of Apc mutant mice to develop tumors in the small intestine (5). To address the issue of tissue specificity, we introduced the mPGES-1 gene deletion onto strain A mice, a line that is highly sensitive to chemical-induced colon cancer (6–8). In the following study, we examined the impact of mPGES-1 genetic status on colon carcinogenesis induced by azoxymethane (AOM), an organospecific carcinogen that causes multiple adenomas in the distal colon (8). Genetic deletion of mPGES-1 affords significant protection against AOM-induced colon cancer. Associated with the striking cancer protection, we identified a critical role for PGE2 in the control of immunoregulatory cell expansion [FoxP3-positive regulatory T cells (Treg)] within the colon-draining mesenteric lymph nodes (MLN), providing a potential mechanism by which inhibition of mPGES-1 and inducible PGE2 synthesis may protect against colorectal cancers (CRC).

Generation of mPGES-1 deletion on A/J background

Male A/J mice were purchased from The Jackson Laboratory and crossed with female mPGES-1 knockout (KO) mice (C57BL/6; ref. 9). mPGES-1 heterozygous mice were backcrossed onto A/J mice for 9 additional generations (N10). N10 heterozygous mice were intercrossed to generate A/J:mPGES-1 KO mice. Genotyping was carried out by tail biopsy. Mice were maintained in a temperature-controlled, light-cycled room and allowed free access to drinking water and standard diet (LM-485; Harlan Teklad).

AOM treatment

Six-week-old wild-type (WT) and KO mice were injected intraperitoneally with AOM (10 mg/kg of body weight; Sigma-Aldrich) or vehicle control (0.9% NaCl) once a week for a total of 6 weeks. Twenty weeks after the last injection, mice were sacrificed and blood, spleen, MLNs, and colon were harvested for further analysis. Colons were flushed immediately with ice-cold PBS and excised longitudinally. Specimens were fixed flat in 10% neutral buffered formalin for 4 hours and stored in 70% ethanol. Animal experiments were conducted after approval by the Animal Care Committee (ACC/IACUS) at the University of Connecticut Health Center.

Quantification of lesions

Whole-mount colons were stained with 0.2% methylene blue and the number and size of aberrant crypt foci (ACF) and tumors were scored under a dissecting microscope. Colon tumor load per mouse was determined using tumor diameter to calculate the spherical tumor volume (V = 4/3 π r3). The amount of ulcerated tissue was determined as the percentage across the entire length of colon (n = 10 per group).

Immunohistochemistry

Colons were paraffin embedded and sectioned at 5-μm thickness. Sections were treated with 1% to 3% hydrogen peroxide, blocked, and incubated with anti-APC (1:800; Millipore), anti-PCNA (1:150; Novocastra Laboratories Ltd.), anti-PECAM1 (1:500; Santa Cruz Biotechnologies, Inc.), anti-β-catenin (1:2,000; Sigma-Aldrich), anti-cleaved caspase-3 (1:200; Cell Signaling Technology Inc.), anti-cyclinD1 (1:20; Novus Biologicals), anti-mPGES-1 (1:5,000; Abnova), and anti-Ki-67 (1:50; Dako North America, Inc.). Sections were incubated with biotinylated secondary antibody, followed by ABC reagent (Vector Laboratories Inc.). Signal was detected using 3,3′-diaminobenzidine (DAB) solution (Vector Laboratories). Tissues were counterstained with hematoxylin.

Immunofluorescence microscopy

Following antigen retrieval, sections were blocked and incubated with anti-mPGES-1 (1:5,000; Abnova) and then incubated with secondary antibody conjugated with Cy5 (1:500; Millipore). Nuclei were stained with Sytox Orange (1:10,000; Invitrogen). Staining was visualized by confocal microscopy using a Zeiss LSM 510/Confocor II and images were analyzed by LSM image browser software.

Flow cytometry

RBC-depleted spleens and MLN cells were resuspended with staining buffer (balanced salt solution, 3% FBS and 0.1% sodium azide), followed by blocking solution containing normal mouse serum, anti-Fc receptor supernatant from the 2.4 G2 hybridoma (10), and human γ-globulin. Cells were incubated with labeled primary antibodies (CD4, CD8, CD11b, Gr-1 from eBioscience; Ki-67 from BD Biosciences) and analyzed by flow cytometry as described before (11). Intracellular staining of FoxP3 was conducted according to manufacturer's protocol (eBioscience).

In vitro lymphocytes stimulation

Spleens and MLNs were harvested from 20- to 25-week-old untreated female A/J mice, and 1 × 106 cells were stimulated with phorbol-12-myristate-13-acetate (PMA; 50 ng/mL; Sigma) and ionomycin (1 μg/mL; Sigma) for 4 hours in the presence of Brefeldin A (10 μg/mL; Sigma). Intracellular staining was conducted for interleukin (IL) 10, IFN-γ, and Foxp3 (eBioscience,) as described earlier (n = 6 per group).

Histologic evaluation

Colon histology was evaluated on Swiss-rolled hematoxylin and eosin (H&E) sections by a board-certified pathologist (T.T.). Colonic crypt dysplasia was diagnosed according to established criteria (12), and colon tumors were further diagnosed using histopathologic descriptions (13).

PGE2 and serum cytokine analyses

Serum was prepared from blood and samples were purified using a PGE2 affinity column (Cayman Chemical). PGE2 concentrations were determined by ELISA (Cayman Chemical; n = 13 per group). Serum cytokine levels were determined using a Bio-Plex Pro assay (Bio-Rad Laboratories, Inc.; n = 5 per group).

Measurement of the proliferative zone

Quantification of the proliferative zone was assessed on proliferating cell nuclear antigen (PCNA)-stained tissues, randomly selecting 25 crypts per mouse for analysis (n = 5 per group). The ratio of positive cells to total cells within the crypt was calculated for each colon, and an average of the ratios were compared between WT and mPGES-1 KO mice.

Statistical analyses

Statistical analyses of tumor size and multiplicity, as well as a comparison of PGE2 levels and the frequency of immune cells using fluorescence-activated cell-sorting (FACS) analysis, were conducted by Student's t test. A value of P < 0.05 was considered statistically significant.

mPGES-1 deletion suppresses colon carcinogenesis

mPGES-1 KO mice and WT littermates were injected with AOM and colons were harvested for analysis 20 weeks after the last injection. In response to AOM treatment, WT mice developed multiple, large, and highly vascularized tumors, primarily confined to the distal colon (Fig. 1A, arrows). In mPGES-1 KO mice, however, only several colons had macroscopically visible tumors (Fig. 1A). Tumor enumeration revealed a remarkable suppression (up to 85%) in mPGES-1 KO mice (33.6 ± 2.0 vs. 5.0 ± 0.7 in WT and KO, respectively; P < 0.0001; Fig. 1B), whereas tumor load was reduced by up to 90% (264.0 ± 29.0 vs. 24.3 ± 4.3 in WT and KO, respectively; P < 0.0001; Fig. 1C). Despite the virtually complete protection against tumor formation, the total number of ACF, a preneoplastic lesion common to the distal colon, was reduced by less than 40% (32.4 ± 2.5 vs. 20.7 ± 2.3 in WT and KO, respectively; P < 0.002; Fig. 1D). The most effective protection occurred in ACF of intermediate size, including those with 2 to 3 (16.0 ± 1.4 vs. 10.0 ± 1.4 in WT and KO, respectively; P < 0.005) and 4 to 6 crypts per focus (10.4 ± 1.3 vs. 6.3 ± 0.9 in WT and KO, respectively; P < 0.01).

Figure 1.

Genetic deletion of mPGES-1 suppresses AOM-induced colon cancer. A, representative whole-mount colons showing numerous large, well-vascularized tumors in the WT mice (arrows). B, size distribution and total number of tumors per colon rounded to the nearest whole number, as well as total tumor volume (mm3). C, size distribution and total number of ACF. Each data point represents an individual mouse. Bars indicate means ± SEM. *, P < 0.05 compared with WT mice.

Figure 1.

Genetic deletion of mPGES-1 suppresses AOM-induced colon cancer. A, representative whole-mount colons showing numerous large, well-vascularized tumors in the WT mice (arrows). B, size distribution and total number of tumors per colon rounded to the nearest whole number, as well as total tumor volume (mm3). C, size distribution and total number of ACF. Each data point represents an individual mouse. Bars indicate means ± SEM. *, P < 0.05 compared with WT mice.

Close modal

In WT mice, analysis of tumor histology identified primarily 2 forms of large adenomas, characterized by either a pedunculated or flat morphology (Fig. 2, WT). The tubular adenomas often exhibited an elongated structure with a stalk (Fig. 2, arrow). In the mPGES-1 KO mice, however, only 1 of 19 mice developed a large adenoma (>3 mm), which had either a flat or a slightly raised morphology (Fig. 2, KO). Microadenomas were found in the colons from either genotype, although carcinomas in situ were limited to the WT mice (Fig. 2, WT). The microadenomas showed slight, moderate, or severe nuclear atypia without evidence of expansion and invasive growth, characteristic of AOM-induced tumors occurring in this model (refs. 7, 12; Fig. 2). The morphology of the adenomas was similar between genotypes, comprised largely of microscopically tubular structures. However, tumors in WT mice were considerably larger, with frequent compression of surrounding normal crypts. In several cases, there was evidence for moderately differentiated tubular carcinomas in situ with invasive growth (Fig. 2, WT). Analysis of crypt dynamics revealed that within the normal colonic epithelium, the absence of mPGES-1 did not affect overall crypt length, nor alter the size of the proliferative compartment in comparison to the WT colons (Supplementary Fig. S1).

Figure 2.

Evaluation of colonic lesions. Tumors in WT mice exhibit tubular or flat adenoma, whereas mPGES-1 KO mice only develop flat or slightly raised adenomas. Microadenomas and adenomas were found in the colons of both genotypes. Carcinomas in situ were identified only in the WT colons. Lesions are delineated by a dotted line. n = 14 in WT and n = 19 in KO mice. Scale bars as indicated.

Figure 2.

Evaluation of colonic lesions. Tumors in WT mice exhibit tubular or flat adenoma, whereas mPGES-1 KO mice only develop flat or slightly raised adenomas. Microadenomas and adenomas were found in the colons of both genotypes. Carcinomas in situ were identified only in the WT colons. Lesions are delineated by a dotted line. n = 14 in WT and n = 19 in KO mice. Scale bars as indicated.

Close modal

mPGES-1 status does not affect tumor markers

The profound suppression in tumor growth observed in the mPGES-1 KO mice raised the possibility that PGE2 levels may directly affect cell turnover within the tumor epithelium. To evaluate this possibility, colon tumors were examined immunohistochemically for PCNA staining (proliferation), and cleaved caspase-3, which detects an earlier stage of apoptosis in cells that have not yet undergone major morphologic changes (14). A total of 10 colons from each genotype were selected for immunohistochemical analyses. Representative adenomas from a WT and mPGES-1 KO colon are shown in Figure 3A. Intense PCNA staining was present throughout the tumor epithelium, regardless of mPGES-1 genotype and independent of tumor size (Fig. 3A, PCNA). Cleaved caspase-3 immunostaining revealed few apoptotic cells within the normal crypts (data not shown), and their frequency was unaffected by mPGES-1 status, nor affected by tumor size (Fig. 3A, cleaved caspase-3). These observations suggest that mPGES-1 status does not influence cell turnover in the AOM colon tumor model.

Figure 3.

Immunohistochemical analysis of colon tumor markers. A, representative serial sections of colons showing staining for PCNA, cleaved caspase-3, and PECAM-1, where positive staining is indicated by the arrows. Boxed areas in H&E sections were enlarged to show the positive staining. Scale bars as indicated. B, representative images of large and small tumors from each genotype stained for APC and β-catenin. Tumor cells from either genotype lack expression of APC (arrows) compared with adjacent normal crypts (arrowheads), independent of tumor size. Similarly, β-catenin staining is increased in the tumor cells (arrows) compared with adjacent normal cells (arrowheads), independent of genotype or tumor size. n = 10 per group. Scale bars as indicated.

Figure 3.

Immunohistochemical analysis of colon tumor markers. A, representative serial sections of colons showing staining for PCNA, cleaved caspase-3, and PECAM-1, where positive staining is indicated by the arrows. Boxed areas in H&E sections were enlarged to show the positive staining. Scale bars as indicated. B, representative images of large and small tumors from each genotype stained for APC and β-catenin. Tumor cells from either genotype lack expression of APC (arrows) compared with adjacent normal crypts (arrowheads), independent of tumor size. Similarly, β-catenin staining is increased in the tumor cells (arrows) compared with adjacent normal cells (arrowheads), independent of genotype or tumor size. n = 10 per group. Scale bars as indicated.

Close modal

In contrast to our previous findings, whereby deletion of mPGES-1 was found to disrupt neovessel growth within small intestinal tumors in ApcΔ14/+ mice (4), mPGES-1 deletion did not directly affect PECAM-1 staining within and adjacent to AOM-induced colon tumors (Fig. 3A, PECAM-1). Even in the smallest colon lesions examined in the mPGES-1 KO mice, PECAM-1 staining within the tumor stroma and surrounding colonic mucosa showed the presence of well-formed vascular structures (arrows; Fig. 3A, PECAM-1). The difference in PECAM-1 staining between these 2 studies, however, may result from the dissimilar experimental systems employed including differing genetic backgrounds and distinct mechanisms of tumor initiation.

We next examined the possibility that disruption of PGE2 formation may directly impact Wnt signaling, an effect that was shown earlier in adenomatous polyposis coli (APC)-deficient DLD-1 colon cancer cells (15). Surprisingly, loss of APC protein, with increased cytoplasmic staining and nuclear localization of β-catenin, was equivalent within tumors regardless of mPGES-1 genotype or tumor size (Fig. 3B). The loss of APC protein is consistent with previous findings showing that AOM-induced tumors do not express the full-length protein (16, 17). Taken together, these data suggest that the cancer suppression associated with reduced PGE2 formation is not related to aberrant cell turnover or dysregulated β-catenin signaling in transformed epithelial cells.

mPGES-1 is expressed in the stroma in the colon

To define the localization of mPGES-1, immunofluorescence imaging was done on colonic mucosa prepared from mice harboring tumors. In the WT colons, we identified increased expression of mPGES-1 localized primarily at the apical surface of the tumor stroma (Fig. 4). Positive staining was also found within the stroma immediately adjacent to the tumors (ref. 18; Fig. 4, arrows). Similar to that reported by Murakami and colleagues (19), mPGES-1 staining was confined to the perinuclear region of the cells (Fig. 4). In addition, the expression of mPGES-1 was observed within multiple cell types including macrophages and fibroblasts (ref. 20; Supplementary Fig. S2). The location of mPGES-1 indicates that the primary source of inducible PGE2 originates within the tumor stroma (21). Therefore, an alternative possibility for tumor suppression is that genetic deletion of mPGES-1 interrupts localized production of PGE2 within the tumor stroma, eliciting effects that extend into the epithelial compartment.

Figure 4.

Immunolocalization of mPGES-1 in tumor stroma. Immunofluorescence detection of mPGES-1 in tumor and adjacent normal colonic mucosa after AOM exposure. T identifies tumor area (delineated by dotted line). Arrows in the merged images indicate the presence of mPGES-1–expressing cells at the apical surface of the tumor and also within the adjacent tumor stroma in WT mice. mPGES-1 was localized to the perinuclear region of stromal cells abutting the tumor. Scale bars as indicated.

Figure 4.

Immunolocalization of mPGES-1 in tumor stroma. Immunofluorescence detection of mPGES-1 in tumor and adjacent normal colonic mucosa after AOM exposure. T identifies tumor area (delineated by dotted line). Arrows in the merged images indicate the presence of mPGES-1–expressing cells at the apical surface of the tumor and also within the adjacent tumor stroma in WT mice. mPGES-1 was localized to the perinuclear region of stromal cells abutting the tumor. Scale bars as indicated.

Close modal

The presence of mucosal ulcerations in mPGES-1 KO mice

Further evaluation of colon histology in the mPGES-1 KO mice revealed the presence of synchronous, localized mucosal ulcerations affecting up to 15% of the colonic epithelium. These cryptal lesions developed independently of AOM treatment and were characterized histologically by the presence of regenerative atypia (Fig. 5A). Mucosal ulcerations within crypt abscesses resembled the active phase of ulcerative colitis. Regenerative crypts adjacent to the ulcerated areas, as well as infiltrating immune cells, were positive for Ki-67, indicating active cell proliferation (Fig. 5A, Ki-67). However, these regenerative crypts did not share other molecular features typically associated with neoplasia. For example, APC expression was largely retained compared with the extensive loss of APC protein observed in dysplastic adenomatous crypts in the mPGES-1 KO mice (Fig. 5B, APC). Importantly, we found no evidence for β-catenin activation within these regenerative crypt lesions, with plasma membrane staining observed in all cases examined (Fig. 5B, β-catenin). Although cyclinD1, a key β-catenin target, showed intermittent nuclear staining within these epithelial structures (Fig. 5B, cyclinD1), the normal status of APC expression and β-catenin localization within these colonic structures support their nonneoplastic nature.

Figure 5.

Histologic features of localized colonic ulcerations. A, a representative localized ulceration in the colon of a mPGES-1 KO mouse containing regenerative crypts (arrowheads). Highly proliferative cells within the regenerative crypts are detected by Ki-67 staining. Intense Ki-67 staining is also seen in infiltrating immune cells within the colonic mucosa. B, comparison of tumor-related markers in serial sections of tumors and mucosal ulcers in mPGES-1 KO mice. Enlarged areas are identified by the box. Scale bars as indicated.

Figure 5.

Histologic features of localized colonic ulcerations. A, a representative localized ulceration in the colon of a mPGES-1 KO mouse containing regenerative crypts (arrowheads). Highly proliferative cells within the regenerative crypts are detected by Ki-67 staining. Intense Ki-67 staining is also seen in infiltrating immune cells within the colonic mucosa. B, comparison of tumor-related markers in serial sections of tumors and mucosal ulcers in mPGES-1 KO mice. Enlarged areas are identified by the box. Scale bars as indicated.

Close modal

Reduced frequency of CD4+FoxP3+ Tregs in the draining MLNs of the mPGES-1 null mice

The mild and localized chronic inflammation observed within the colons of mPGES-1 KO mice was further substantiated by the presence of macroscopically inflamed MLNs, with a significant expansion of total lymphocytes (1.6 ± 0.3 vs. 7.4 ± 1.5 in WT and KO, respectively; P < 0.006;Fig. 6A). Total numbers of CD4+ and CD8+ cells were also markedly elevated (0.9 ± 0.2 vs. 2.9 ± 0.5 for CD4+ in WT and KO, respectively; P < 0.004 and 0.2 ± 0.04 vs. 0.8 ± 0.2 for CD8+ in WT and KO, respectively; P < 0.01, respectively; Fig. 6A), presumably a direct result of the ongoing localized inflammation. In the spleen, however, there were no significant differences in the total numbers of both CD4+ and CD8+ cells (Fig. 6A). Correspondingly, serum PGE2 concentrations were moderately (P < 0.05) lower in the mPGES-1 KO than in WT mice (Supplementary Fig. S3A). Moreover, the concentration of a panel of pro- and anti-inflammatory cytokines in the serum was mostly unchanged between genotypes, confirming the localized effect associated with mPGES-1 deletion (Supplementary Fig. S3B). The only exception was a significant decrease in IL-1α in mPGES-1 KO mice, which was recently shown to be regulated by PGE2 (22) and might be indicative of a stronger chronic inflammatory response.

Figure 6.

Flow cytometry of cells in MLNs and spleens. A, total numbers of cells in MLN and spleen, including the number of CD4+ and CD8+ T cells. B, representative FACS analysis showing the frequency of CD4 FoxP3 double-positive Tregs. Quantification of FACS analyses is expressed as means ± SEM, n = 9 per group. C, representative FACS analysis showing frequency of Gr-1 CD11b double-positive MDSCs. Quantification of FACS analysis is expressed as means ± SEM, n = 8 in WT and n = 6 in KO mice. *, P < 0.05; NS, not significant compared with WT mice.

Figure 6.

Flow cytometry of cells in MLNs and spleens. A, total numbers of cells in MLN and spleen, including the number of CD4+ and CD8+ T cells. B, representative FACS analysis showing the frequency of CD4 FoxP3 double-positive Tregs. Quantification of FACS analyses is expressed as means ± SEM, n = 9 per group. C, representative FACS analysis showing frequency of Gr-1 CD11b double-positive MDSCs. Quantification of FACS analysis is expressed as means ± SEM, n = 8 in WT and n = 6 in KO mice. *, P < 0.05; NS, not significant compared with WT mice.

Close modal

We next investigated the immunoregulatory mechanisms that may underlie colonic inflammation in the mPGES-1 KO mice. PGE2 has been shown in vitro to enhance the differentiation of naive CD4+ T cells into FoxP3-positive Tregs that have the potential to suppress effector T-cell function (23). Furthermore, Tregs play an important regulatory role in gastrointestinal immunity (24). As shown in Figure 6B, in the MLNs of mPGES-1 KO mice, the frequency of CD4 FoxP3 double-positive cells was reduced by 55% compared than in WT mice (21.1 ± 1.1 vs. 11.7 ± 1.3 in WT and KO, respectively; P < 0.0004). Importantly, this effect was not systemic, as the composition of Tregs within the spleen was unaffected by genotype (Fig. 6B).

We also examined the possibility that a population of myeloid-derived suppressor cells (MDSC), immunomodulatory cells that are often increased in tumor-bearing mice (25), may be expanded in mPGES-1 KO mice in response to the localized mucosal ulcerations. As anticipated, increased levels of GR-1 CD11b double-positive MDSCs were found in the MLN (0.03 ± 0.02 vs. 0.20 ± 0.03 in WT and KO, respectively; P < 0.00004) and spleen (2.08 ± 0.40 vs. 8.37 ± 2.76 in WT and KO, respectively; P < 0.01; Fig. 6C). However, the frequency of MDSCs was modest in comparison to changes found in other mouse tumor models. For example, in some cases, the spleen can harbor up to 40% of MDSCs within the T-cell population, depending of course on the underlying pathology (26). The present findings suggest that limited expansion of MDSCs in mPGES-1 KO mice, most likely attributed to reduced PGE2 levels (27), contributes to the enhanced inflammatory state that is present within the colon and that may ultimately impede colon tumor progression.

On the basis of the reduced levels of Tregs and the moderate effect on MDSCs, we postulated that additional immunoregulatory mechanisms might also contribute to tumor suppression. Thus to evaluate this possibility, we harvested cells from the spleens and MLNs of untreated WT and mPGES-1 KO mice. The total number of cells harvested from the MLN of the mPGES-1 KO mice was significantly higher in comparison to the WT mice, a result of the localized colonic ulcerations (Supplementary Fig. S4). In addition, the number of CD4+ and CD8+ cells was also markedly higher in the mPGES-1 KO MLN (Supplementary Fig. S4), consistent with our findings in tumor-bearing mice (Fig. 6A). Following a 4-hour stimulation with PMA/ionomycin, the ability of CD4+ cells to produce IL-10 or IFN-γ was slightly impaired in the mPGES-1 KO group (Supplementary Fig. S4). These observations suggest that mPGES-1 deficiency may affect the production of regulatory T type 1 cells (Tr1), another type of immunoregulatory cell present within the gut mucosa (28).

Elevated prostanoid production in the colon plays a key role in cancer pathogenesis and efforts have been made to suppress this pathway, primarily via inhibition of COX-2 activity. Although long-term COX-2 inhibition can be effective, it has also been associated with a number of adverse effects, notably cardiovascular and gastrointestinal (GI) toxicities (29). Evidence from several tumor models provides the rationale for the development of alternative chemoprevention targets within the arachidonic acid pathway including the terminal PGE2 synthase, mPGES-1 (3). In the present study, we provide evidence that suppression of inducible PGE2 production through genetic deletion of mPGES-1 effectively reduces colon cancer development. We also go on to show that suppressing inducible PGE2 formation influences cancer development in part by promoting an effective immune response to the tumor.

Remarkably, tumor suppression was so effective that only 1 of 19 mPGES-1 KO mice (5.3%) developed a colon tumor exceeding 3 mm in size. Despite this protection afforded to the colon, however, mPGES-1 deletion did not influence the frequency of ACF to the same extent. This latter observation is consistent with the recent findings of Cho and colleagues (30) who reported that within a subset of patients on the Adenoma Prevention with Celecoxib trial, adenoma suppression by celecoxib treatment was not correlated with changes in the density of ACF within the distal colorectum. It is possible that at least for agents that target the COX-2 pathway, ACF do not provide a surrogate marker for colon cancer suppression.

PGE2 is a pleiotropic molecule that is formed within a variety of cell types and can elicit effects that are both cell- and tissue-context dependent. The precise location of inducible PGE2 formation, however, remains somewhat controversial. For example, it is broadly accepted that tumor cell–derived PGE2 promotes tumor growth through an autocrine mechanism. Consistent with this mechanism, mPGES-1 expression has been identified directly within the epithelial cells of colon tumors (31–33). In the present study, however, we found that mPGES-1 was localized primarily within the tumor stroma, indicating that inducible formation of PGE2 may impair tumor expansion via non–cell autonomous mechanisms. This finding is consistent with the results of Kamei and colleagues (32), who showed that the growth of Lewis lung carcinoma (LLC) tumor cells explanted into an mPGES-1–deficient host was markedly impaired in comparison to the growth observed in an mPGES-1–competent host. In addition, a number of studies have found COX-2 expression to be confined to the tumor stroma (reviewed in ref. 34).

The depletion of inducible PGE2 formation is associated with the development of colonic mucosal abnormalities that are reminiscent of ulcerative colitis. The lesions are restricted to the large intestine, and the histologic features of these lesions consist of crypt erosion and an influx of inflammatory cells. Interestingly, Hara and colleagues (35) recently reported that mPGES-1 KO mice show enhanced susceptibility to dextran sodium sulfate (DSS)-induced ulcerative colitis, confirming a critical role for PGE2 in maintaining colonic epithelial barrier function under conditions of chemical-induced stress. It is possible that the localized ulcerations present within the colons of the mPGES-1 KO mice induce a chronic inflammatory condition. We further speculate that this underlying inflammation may actually be a contributing factor in the suppression of colon tumors observed in the present study.

PGE2 is among the most potent immunoregulatory molecules within the intestinal mucosa. In addition to its modulating effects on normal gut barrier function and mucosal response to pathogens (36), inducible formation of PGE2 also plays a critical role in the immunosuppression associated with advanced neoplasia (37). Tregs, with the potential to suppress effector T-cell function (38, 39) have been shown to play an important immunomodulatory role within the GI tract (24, 40). Within the tumor microenvironment, PGE2 has been reported to enhance Treg differentiation by inducing the expression of Foxp3 in naive CD4+ T cells (23, 41, 42). In CRC patients, increased levels of Tregs were identified within the tumors as well as in the regional lymph nodes (43). Moreover, the effect of Tregs on the production of proinflammatory cytokines was reversed by treatment with nonsteroidal anti-inflammatory drugs (NSAID), further evidence for Treg dependence on PGE2 during tumor evolution (43). Given the direct influence that PGE2 elicits on FoxP3 expression in T cells, it is entirely possible that mPGES-1 deficiency may result in a persistent overreactive immune response due to the loss of functional activation of Tregs.

Interestingly, the present study shows that the impaired immunoregulatory response in the mPGES-1 KO mice, reflected by the spontaneous development of localized ulcerations, was not entirely accounted for by attenuated Treg expansion. mPGES-1 deletion also modestly affected the levels of MDSCs and Tr1-like cells, suggesting that the absence of inducible PGE2 formation may disrupt fundamental immunomodulatory mechanisms within the tumor microenvironment. One possibility is that mPGES-1 deficiency causes a shift in cytokine profiles during tumorigenesis. In fact, Monrad and colleagues (44) recently showed that mPGES-1–deficient bone marrow–derived dendritic cells (BMDC) had decreased production of IL-12 in response to lipopolysaccharide (LPS) stimulation. Furthermore, our preliminary data show that MLN cells harvested from the mPGES-1 KO mice produce higher levels of several cytokines when compared with similarly stimulated WT cells (data not shown). Because the mPGES-1 genotype did not affect systemic cytokine profiles with the exception of IL-1α, a more detailed analysis of tissue-specific cytokine profiles is warranted.

A number of studies suggest that chronic inflammation may play an important role in the pathogenesis of up to 20% of human cancers (45). In particular, long-standing inflammatory bowel disease (IBD) is considered a significant risk factor for CRC (46). Although the present data appear to contradict these earlier observations, we postulate that the underlying inflammation present in mPGES-1 KO mice, resulting from the mild and localized colonic ulceration, may actually confer protection against tumor progression by providing a mechanism for active clearance of cancer-initiating cells. Consistent with this hypothesis, an earlier study by Tanaka and colleagues (13) showed that mice administered DSS prior to a single injection of AOM failed to develop colon tumors 20 weeks later. In the present study, mPGES-1 KO mice did not exhibit clinical signs of severe ulcerative colitis, such as rectal bleeding and excessive weight loss (data not shown), despite the presence of these benign, localized mucosal ulcerations. Of course, the possibility exists that the mild inflammation that is present within the colons of the mPGES-1 KO mice may contribute to subsequent cancer risk. However, without additional genetic hits, these lesions may not have the capacity to progress to cancer (47). Therefore, additional studies to better define the mechanisms by which selective suppression of PGE2 directly modulates antitumor immunity and contributes to colon cancer suppression are underway. These studies will ultimately enable the development of effective therapeutic strategies for targeting mPGES-1 for cancer prevention.

No potential conflicts of interest were disclosed.

The authors thank Dr. Robert Clark in Department of Immunology at University of Connecticut Health Center for his advice on designing experiments for Treg analyses.

This work was supported by NIH grant CA-125691 and CA-114635 (D.W. Rosenberg).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1.
Radmark
O
,
Samuelsson
B
. 
Microsomal prostaglandin E synthase-1 and 5-lipoxygenase: potential drug targets in cancer
.
J Intern Med
2010
;
268
:
5
14
.
2.
Samuelsson
B
,
Morgenstern
R
,
Jakobsson
PJ
. 
Membrane prostaglandin E synthase-1: a novel therapeutic target
.
Pharmacol Rev
2007
;
59
:
207
24
.
3.
Nakanishi
M
,
Gokhale
V
,
Meuillet
EJ
,
Rosenberg
DW
. 
mPGES-1 as a target for cancer suppression: a comprehensive invited review “Phospholipase A2 and lipid mediators”
.
Biochimie
2010
;
92
:
660
4
.
4.
Nakanishi
M
,
Montrose
DC
,
Clark
P
,
Nambiar
PR
,
Belinsky
GS
,
Claffey
KP
, et al
Genetic deletion of mPGES-1 suppresses intestinal tumorigenesis
.
Cancer Res
2008
;
68
:
3251
9
.
5.
Moser
AR
,
Luongo
C
,
Gould
KA
,
McNeley
MK
,
Shoemaker
AR
,
Dove
WF
. 
ApcMin: a mouse model for intestinal and mammary tumorigenesis
.
Eur J Cancer
1995
;
31A
:
1061
4
.
6.
Nambiar
PR
,
Nakanishi
M
,
Gupta
R
,
Cheung
E
,
Firouzi
A
,
Ma
XJ
, et al
Genetic signatures of high- and low-risk aberrant crypt foci in a mouse model of sporadic colon cancer
.
Cancer Res
2004
;
64
:
6394
401
.
7.
Papanikolaou
A
,
Wang
QS
,
Papanikolaou
D
,
Whiteley
HE
,
Rosenberg
DW
. 
Sequential and morphological analyses of aberrant crypt foci formation in mice of differing susceptibility to azoxymethane-induced colon carcinogenesis
.
Carcinogenesis
2000
;
21
:
1567
72
.
8.
Rosenberg
DW
,
Giardina
C
,
Tanaka
T
. 
Mouse models for the study of colon carcinogenesis
.
Carcinogenesis
2009
;
30
:
183
96
.
9.
Uematsu
S
,
Matsumoto
M
,
Takeda
K
,
Akira
S
. 
Lipopolysaccharide-dependent prostaglandin E(2) production is regulated by the glutathione-dependent prostaglandin E(2) synthase gene induced by the Toll-like receptor 4/MyD88/NF-IL6 pathway
.
J Immunol
2002
;
168
:
5811
6
.
10.
Unkeless
JC
,
Kaplan
G
,
Plutner
H
,
Cohn
ZA
. 
Fc-receptor variants of a mouse macrophage cell line
.
Proc Natl Acad Sci U S A
1979
;
76
:
1400
4
.
11.
Menoret
A
,
Myers
LM
,
Lee
SJ
,
Mittler
RS
,
Rossi
RJ
,
Vella
AT
. 
TGFbeta protein processing and activity through TCR triggering of primary CD8+ T regulatory cells
.
J Immunol
2006
;
177
:
6091
7
.
12.
Nambiar
PR
,
Nakanishi
M
,
Gupta
RA
,
Cheung
E
,
Firouzi
A
,
Ma
XJ
, et al
Molecular signatures of high and low risk aberrant crypt foci in a mouse model of sporadic colon cancer
.
Dig Dis Week
2004
:
501
.
13.
Tanaka
T
,
Kohno
H
,
Suzuki
R
,
Yamada
Y
,
Sugie
S
,
Mori
H
. 
A novel inflammation-related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate
.
Cancer Sci
2003
;
94
:
965
73
.
14.
Greenspan
EJ
,
Nichols
FC
,
Rosenberg
DW
. 
Molecular alterations associated with sulindac-resistant colon tumors in ApcMin/+ mice
.
Cancer Prev Res
2010
;
3
:
1187
97
.
15.
Castellone
MD
,
Teramoto
H
,
Williams
BO
,
Druey
KM
,
Gutkind
JS
. 
Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis
.
Science
2005
;
310
:
1504
10
.
16.
Guda
K
,
Upender
MB
,
Belinsky
G
,
Flynn
C
,
Nakanishi
M
,
Marino
JN
, et al
Carcinogen-induced colon tumors in mice are chromosomally stable and are characterized by low-level microsatellite instability
.
Oncogene
2004
;
23
:
3813
21
.
17.
Maltzman
T
,
Whittington
J
,
Driggers
L
,
Stephens
J
,
Ahnen
D
. 
AOM-induced mouse colon tumors do not express full-length APC protein
.
Carcinogenesis
1997
;
18
:
2435
9
.
18.
Takeda
H
,
Sonoshita
M
,
Oshima
H
,
Sugihara
K
,
Chulada
PC
,
Langenbach
R
, et al
Cooperation of cyclooxygenase 1 and cyclooxygenase 2 in intestinal polyposis
.
Cancer Res
2003
;
63
:
4872
7
.
19.
Murakami
M
,
Naraba
H
,
Tanioka
T
,
Semmyo
N
,
Nakatani
Y
,
Kojima
F
, et al
Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2
.
J Biol Chem
2000
;
275
:
32783
92
.
20.
Gudis
K
,
Tatsuguchi
A
,
Wada
K
,
Futagami
S
,
Nagata
K
,
Hiratsuka
T
, et al
Microsomal prostaglandin E synthase (mPGES)-1, mPGES-2 and cytosolic PGES expression in human gastritis and gastric ulcer tissue
.
Lab Invest
2005
;
85
:
225
36
.
21.
Backlund
MG
,
Mann
JR
,
Dubois
RN
. 
Mechanisms for the prevention of gastrointestinal cancer: the role of prostaglandin E2
.
Oncology
2005
;
69
Suppl 1
:
28
32
.
22.
Shao
J
,
Sheng
H
. 
Prostaglandin E2 induces the expression of IL-1alpha in colon cancer cells
.
J Immunol
2007
;
178
:
4097
103
.
23.
Sharma
S
,
Yang
SC
,
Zhu
L
,
Reckamp
K
,
Gardner
B
,
Baratelli
F
, et al
Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer
.
Cancer Res
2005
;
65
:
5211
20
.
24.
Read
S
,
Malmstrom
V
,
Powrie
F
. 
Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation
.
J Exp Med
2000
;
192
:
295
302
.
25.
Ostrand-Rosenberg
S
,
Sinha
P
. 
Myeloid-derived suppressor cells: linking inflammation and cancer
.
J Immunol
2009
;
182
:
4499
506
.
26.
Gabrilovich
DI
,
Nagaraj
S
. 
Myeloid-derived suppressor cells as regulators of the immune system
.
Nat Rev Immunol
2009
;
9
:
162
74
.
27.
Sinha
P
,
Clements
VK
,
Fulton
AM
,
Ostrand-Rosenberg
S
. 
Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells
.
Cancer Res
2007
;
67
:
4507
13
.
28.
Vieira
PL
,
Christensen
JR
,
Minaee
S
,
O'Neill
EJ
,
Barrat
FJ
,
Boonstra
A
, et al
IL-10-secreting regulatory T cells do not express Foxp3 but have comparable regulatory function to naturally occurring CD4+CD25 + regulatory T cells
.
J Immunol
2004
;
172
:
5986
93
.
29.
Wang
D
,
Dubois
RN
. 
The role of COX-2 in intestinal inflammation and colorectal cancer
.
Oncogene
2010
;
29
:
781
8
.
30.
Cho
NL
,
Redston
M
,
Zauber
AG
,
Carothers
AM
,
Hornick
J
,
Wilton
A
, et al
Aberrant crypt foci in the adenoma prevention with celecoxib trial
.
Cancer Prev Res
2008
;
1
:
21
31
.
31.
Golijanin
D
,
Tan
JY
,
Kazior
A
,
Cohen
EG
,
Russo
P
,
Dalbagni
G
, et al
Cyclooxygenase-2 and microsomal prostaglandin E synthase-1 are overexpressed in squamous cell carcinoma of the penis
.
Clin Cancer Res
2004
;
10
:
1024
31
.
32.
Kamei
D
,
Murakami
M
,
Sasaki
Y
,
Nakatani
Y
,
Majima
M
,
Ishikawa
Y
, et al
Microsomal prostaglandin E synthase-1 in both cancer cells and hosts contributes to tumour growth, invasion and metastasis
.
Biochem J
2009
;
425
:
361
71
.
33.
Yoshimatsu
K
,
Golijanin
D
,
Paty
PB
,
Soslow
RA
,
Jakobsson
PJ
,
DeLellis
RA
, et al
Inducible microsomal prostaglandin E synthase is overexpressed in colorectal adenomas and cancer
.
Clin Cancer Res
2001
;
7
:
3971
6
.
34.
Williams
CS
,
DuBois
RN
. 
Prostaglandin endoperoxide synthase: why two isoforms?
Am J Physiol
1996
;
270
:
G393
400
.
35.
Hara
S
,
Kamei
D
,
Sasaki
Y
,
Tanemoto
A
,
Nakatani
Y
,
Murakami
M
. 
Prostaglandin E synthases: understanding their pathophysiological roles through mouse genetic models
.
Biochimie
2010
;
92
:
651
9
.
36.
Montrose
DC
,
Kadaveru
K
,
Ilsley
JN
,
Root
SH
,
Rajan
TV
,
Ramesh
M
, et al
cPLA2 is protective against COX inhibitor-induced intestinal damage
.
Toxicol Sci
2010
;
117
:
122
32
.
37.
Tilley
SL
,
Coffman
TM
,
Koller
BH
. 
Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes
.
J Clin Invest
2001
;
108
:
15
23
.
38.
Sakaguchi
S
,
Sakaguchi
N
,
Asano
M
,
Itoh
M
,
Toda
M
. 
Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases
.
J Immunol
1995
;
155
:
1151
64
.
39.
Seddon
B
,
Mason
D
. 
Regulatory T cells in the control of autoimmunity: the essential role of transforming growth factor beta and interleukin 4 in the prevention of autoimmune thyroiditis in rats by peripheral CD4(+)CD45RC- cells and CD4(+)CD8(-) thymocytes
.
J Exp Med
1999
;
189
:
279
88
.
40.
Maloy
KJ
,
Salaun
L
,
Cahill
R
,
Dougan
G
,
Saunders
NJ
,
Powrie
F
. 
CD4+CD25+ T(R) cells suppress innate immune pathology through cytokine-dependent mechanisms
.
J Exp Med
2003
;
197
:
111
9
.
41.
Mahic
M
,
Yaqub
S
,
Johansson
CC
,
Tasken
K
,
Aandahl
EM
. 
FOXP3+CD4+CD25+ adaptive regulatory T cells express cyclooxygenase-2 and suppress effector T cells by a prostaglandin E2-dependent mechanism
.
J Immunol
2006
;
177
:
246
54
.
42.
Baratelli
F
,
Lin
Y
,
Zhu
L
,
Yang
SC
,
Heuzé-Vourc'h
N
,
Zeng
G
, et al
Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells
.
J Immunol
2005
;
175
:
1483
90
.
43.
Yaqub
S
,
Henjum
K
,
Mahic
M
,
Jahnsen
FL
,
Aandahl
EM
,
Bjørnbeth
BA
, et al
Regulatory T cells in colorectal cancer patients suppress anti-tumor immune activity in a COX-2 dependent manner
.
Cancer Immunol Immunother
2008
;
57
:
813
21
.
44.
Monrad
SU
,
Kojima
F
,
Kapoor
M
,
Kuan
EL
,
Sarkar
S
,
Randolph
GJ
, et al
Genetic deletion of mPGES-1 abolishes PGE2 production in murine dendritic cells and alters the cytokine profile, but does not affect maturation or migration
.
Prostaglandins Leukot Essent Fatty Acids
2011
;
84
:
113
21
.
45.
Aggarwal
BB
,
Vijayalekshmi
RV
,
Sung
B
. 
Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe
.
Clin Cancer Res
2009
;
15
:
425
30
.
46.
Waldner
MJ
,
Neurath
MF
. 
Colitis-associated cancer: the role of T cells in tumor development
.
Semin Immunopathol
2009
;
31
:
249
56
.
47.
Mladenova
D
,
Daniel
JJ
,
Dahlstrom
JE
,
Bean
E
,
Gupta
R
,
Pickford
R
, et al
The NSAID sulindac is chemopreventive in the mouse distal colon but carcinogenic in the proximal colon
.
Gut
2011
;
60
:
350
60
.

Supplementary data